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Introduction
Transcriptional gene silencing (TGS) results when small or 
long noncoding RNAs (ncRNAs) target epigenetic modifica-
tions  to  genetic  loci  containing  gene  promoters  (reviewed 
in ref. 1,2). TGS with small ncRNAs was first observed in 
plants and shown to result in stable long-term gene silencing 
and was shown to be mechanistically linked to RNA-directed 
DNA methylation of the gene promoter.3,4 To date, the abil-
ity of ncRNAs to direct TGS has been shown in a variety of 
organisms  such  as  yeast  (Schizosaccharomyces  pombe), 
flies  (Drosophila),  worms  (Caenorhabditis  elegans),  and 
human cells (reviewed in ref. 5,6). In human cells, the induc-
tion of TGS requires a relatively short duration of exposure 
to a small ncRNA, which can include small interfering RNA 
(siRNA), short hairpin RNA (shRNA), or single-stranded anti-
sense RNAs (asRNA).7 Initial exposure to the small ncRNA 
results  in  histone  modifications,8,9  followed  later,  in  some 
cases, by DNA methylation at the targeted loci.10,11 This form 
of silencing can be long-lasting and heritable as the epige-
netic marks are passed on to daughter cells and thus retained 
through cell division.10 Notably, TGS has been observed to 
be functional in vivo suggesting therapeutic relevance.12–14
Studies of canonical small antisense ncRNAs targeted to 
gene promoters have revealed the involvement of proteins: 
Argonaute 1 (Ago-1), histone deacetylase-1 (HDAC-1), and 
DNA  methyltransferase  3a  (DNMT3a)7,11,15,16  all  of  which 
are required for the induction of TGS in human cells. The 
promoter-targeted ncRNAs are able to target the promoter 
region by recognizing a low-copy promoter-associated RNA 
that spans the promoter and may act as a scaffold for the 
recruitment of the transcriptional silencing complex contain-
ing  HDAC-1,  Ago-1,  DNMT3a,  and  possibly  several  other 
unknown proteins.9,17–20 Recent observations have indicated 
that one class of endogenous RNAs, long antisense ncRNAs, 
are functionally capable of directing TGS in human cells21–23 
and discussed in detail in 2,24,25. These long antisense ncR-
NAs are presumed to function by guiding epigenetic regula-
tory protein complexes to the particular targeted loci, though 
studies delineating this mechanism are limited.21–23 Interest-
ingly suppression of these endogenous ncRNAs can lead to 
derepression and transcriptional gene activation.2,26
Although  much  information  has  been  gleaned  regard-
ing the ability of ncRNAs to modulate gene transcription in 
human cells, it remains unknown as to what extent small syn-
thetic oligonucleotide variants with various backbone chemi-
cal modifications can be utilized to exploit the endogenous 
TGS pathway and epigenetically regulate gene transcription. 
Of particular interest is that synthetic oligonucleotides may 
exhibit  increased  stability  when  compared  to  endogenous 
ncRNA and thus may prove to be an advantageous means 
of inducing long-term TGS. Data presented here suggests 
that particular backbone modifications are tolerated and can 
functionally direct TGS of HIV-1 in human cells but that this 
method,  depending  on  the  modification,  does  not  appear 
to  utilize  the  same  protein  components  as  endogenously 
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expressed asRNAs or siRNAs in directing TGS. This research 
addresses an understudied area that may one day lend itself to 
the development of oligonucleotide-mediated therapeutics.
Results
Chemically  modified  antisense  oligonucleotides 
  effectively suppress LTR transcription
Targeting  of  an  actively  transcribed  gene  promoter  by 
antisense  ncRNA  is  becoming  recognized  as  an  endog-
enous  mode  of  transcriptional  gene  regulation  in  human 
cells.21,22,27,28 Here, we target the LTR-366 site in the human 
immunodeficiency virus type 1 (HIV-1) long terminal repeat 
(LTR)   (Figure 1a). The small asRNA LTR-366 has previously 
been found to direct TGS of HIV-1.7,9,11,29 The target site for 
LTR-366 overlaps a unique nuclear factor-κB (NF-κB) doublet 
in the LTR, a critical element in HIV-1 transcription   (Figure 
1a). Although this site has been shown to be susceptible to 
small asRNA- and siRNA-mediated TGS in vivo,30 the use of 
modified oligonucelotides has not been explored. In order to 
determine the ability of chemically modified antisense oligo-
nucleotides to selectively direct TGS of HIV-1, several vari-
ants with backbone chemical modifications of the LTR-366 
asRNA were synthesized as single-stranded antisense oligo-
nucleotides (Figure 1b). These backbone-modified antisense 
oligonucleotides were transfected into TZM-bl cells containing 
an integrated HIV-1 LTR-driven luciferase reporter construct 
Figure  1  Antisense  oligonucleotide  targeting  of  HIV-1  5′  LTR-mediated  transcription. ( a)  Schematic  representation  depicting 
the HIV-1 5′ LTR and the previously determined as366 small RNA target site. Several transcription factor-binding sites are also shown.   
(b) Backbone-modified oligonucleotides generated against as366 target site. Note the various backbone modifications are: [2′4′]-locked 
ribonucleotide (β), 2′-O-methyl-ribonucleotide (m), and 5-methyl-cytosine (Z), phosphorothioate linkage (*). (c) Various backbone-modified 
single-stranded oligonucleotides, designed to target the LTR-366 site, were cotransfected into TZM-bl indicator cells with a Tat expressing 
plasmid and screened for effects on luciferase expression 48 hours post-transfection. The average from a duplicate sampling of a single 
experiment are shown with the respective ranges. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HIV-1, human immunodeficiency 
virus type 1; LNA, locked nucleic acid; LTR, long terminal repeat; NF-κB, nuclear factor-κB.
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that can be transcriptionally activated by the expression of the 
viral Tat protein. Using this reporter system, the top suppres-
sive candidates were determined (Figure 1c). From this initial 
screen of backbone-modified asRNA, we were able to dis-
cern several variants of the LTR-366 asRNA that were capa-
ble of suppressing Tat-mediated expression of luciferase in 
TZM-bl cells to an equal or higher efficiency than the unmodi-
fied asRNA 366 control. These variants contained 2′OMe and 
2′F (as457), intermittently spaced 2′F (as456) and specific 
LNA–2′ OMe combinations (as452 and as453). The LTR-366 
asRNA variant containing continuous 2′F substitutions was 
ineffective at suppressing luciferase expression (Figure 1a).
LTR-targeted  as452  and  as453  direct  TGS  in  variant 
  specific and unique manner
The observed suppression of luciferase expression by the vari-
ous LTR-366 asRNA variants were indicative of potential TGS, 
but it is also plausible that the oligonucleotides were functional 
via interactions with the 3′ LTR-366, which is also expressed in 
frame with the luciferase transcript and contains the LTR-366 
site. In order to determine whether or not the observed anti-
sense oligonucleotide suppression of HIV-1 involves TGS, we 
suppressed the expression of HDAC-1, Ago-1, and DNMT3a, 
protein components, which have previously been shown to be 
required for si/shRNA-directed TGS of HIV-1.9,11,30,31 The abil-
ity of the two most promising LTR-366 asRNA variants, as452 
and as453, to suppress LTR-driven luciferase expression was 
examined in conjunction with HDAC-1 knockdown. The as452 
and as453 antisense oligonucleotides differ only in that three 
nucleotides from the 3′ end (βZ*βG*βG) have been removed 
in as453 (19mer to 16mer, Figure 1b). The removal of these 
three locked nucleic acid (LNA) nucleotides appeared to affect 
the pathway used as only as452 seemed to require the action 
of HDAC-1   (Figure 2a,b). Owing to this observation, that only 
Figure 2  Mechanistic assessment of antisense oligonucleotide targeting of the HIV-1 LTR. (a,b) The role of HDAC-1 in oligonucle-
otide mediated TGS of HIV-1. TZM-bl cells were treated with siRNAs to suppress HDAC-1 or siRNA R854 (control) (100 nmol/l). Twenty-
four hours later the cultures were transfected with as452 or as453 (100 nmol/l). The cultures were collected 48 hours later and either   
(a) HDAC-1 expression or (b) LTR-mediated expression of luciferase determined by qRT-PCR. (c) The role of DNMT3a in oligonucleotide-
mediated TGS of HIV-1. TZM-bl cells were transfected with control or DNMT3a suppressing shRNA expressing plasmids. Twenty-four 
hours later the cultures were transfected with as452 or the R854 (control) (100 nmol/l). The cultures were collected 48 hours later and 
either luciferase or DNMT3a expression determined by qRT-PCR. (d) Relative level of methylation of the 5′ LTR target region 366 following 
treatment with pTatDSred and subsequent transfection with as452 or R854 (control) (100 nmol/l). Cells were collected 72 hours later and 
assayed using MeDIP and qPCR performed specifically for the region of interest. (e) The role of Ago-1 in as452-mediated TGS. TZM-bl 
cells were transfected with pTatDSred for 24 hours before transfection with either as452 or R854 (control) (100 nmol/l) and a plasmid 
containing a shRNA targeting Ago-1 (shAgo-1) or the same plasmid without insert (shControl). Cells were collected 72 hours later and 
either luciferase or Ago-1 expression assayed using qPCR. (f,g) The effects of 5′ phosphate additions on Ago-1 mediated TGS. TZM-bl 
cells were transfected with pTatDSred with shControl or shAgo-1. Twenty-four hours later the cultures were transfected with either as452 or 
R854 (control) (100 nmol/l) and cellular RNAs collected 72 hours later and luciferase or Ago-1 expression determined by qRT-PCR (f and 
g, respectively). For a–g, the averages of triplicate treated cultures are shown with the standard error of the mean, with the exception being 
e, which shows the standard deviations; P values from a paired t-test are also shown. Ago-1, argonaute 1; DNMT3a, DNA methyltrans-
ferase 3a; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HDAC-1, histone deacetylase-1; HIV-1, human immunodeficiency virus 
type 1; LTR, long terminal repeat; MeDIP, methylated-DNA immunoprecipitation; qPCR, quantitative PCR; qRT-PCR, quantitative reverse 
transcription-PCR; shRNA, short hairpin RNA; siRNA, small interfering RNA; TGS, transcriptional gene silencing.
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as452 appeared to require the action of HDAC-1 to function, 
we surmised that as452 is functional in suppressing HIV-1 
LTR transcription in a TGS-based manner. As such as452 was 
the candidate oligonucleotide explored further.
Previous  work  with  small  ncRNA-directed TGS  in  human 
cells has demonstrated a requirement for DNMT3a (reviewed 
in ref. 6). DNMT3a has been previously reported to form a cel-
lular epigenetic remodeling complex with Ezh2 and HDAC-1.32 
To determine whether there is a requirement of DNMT3a in 
as452-mediated TGS  of  HIV-1  LTR  activity,  we  suppressed 
DNMT3a  expression  by  shRNA  and  assayed  as452  sup-
pression  of  luciferase.  The  suppression  of  DNMT3a,  while 
also having an off-target effect on endogenous LTR-mediated 
expression of luciferase, demonstrated a modest reduction in 
as452-mediated TGS of LTR expressed luciferase   (Figure 2c). 
This reduction was not highly significant, however, previous 
studies have observed that a longer periods of targeting are 
required for extensive DNA methylation (~10 days of sustained 
treatment),10  indicating  that  DNMT3a  involvement  may  be 
reduced in the time frame used for these experiments or that 
as452 does not exert its effects through DNMT3a. Therefore, 
in order to investigate further whether methylation of cytosine 
to 5-cytosine by DNMT3a plays a role in as452 suppression 
of the LTR-366; methylated-DNA immunoprecipitation (MeDIP) 
was performed with an antibody specific to 5-methylcytosine. 
Treatment of cells with either as452 or the control R854 did 
not appear to modulate DNA methylation of the targeted LTR-
366 region ~72 hours post-treatment (Figure 2d); indicating 
that DNMT3a, and de novo DNA methylation, does not play 
an appreciable role in the mechanism of as452-directed silenc-
ing. Taken together these data suggest that as452 appears to 
modulate TGS via an HDAC-1 dependent but DNMT3a inde-
pendent manner.
Ago-1 has also been found to be required for siRNA-di-
rected TGS in human cells.16,33 In order to confirm whether 
or not as452 was operative in a manner that required Ago-1; 
we knocked down the expression of Ago-1 using shRNA. The 
suppression of Ago-1 did not appear to affect as452-mediated 
suppression of LTR expressed luciferase (Figure 2e). Unlike 
endogenously processed RNA; the chemically modified oligo-
nucleotides contain no 5′ phosphate group. It has recently been 
proposed that a 5′ phosphate on the guide strand is essential 
for proper loading of microRNA into Ago in Drosophila mela-
nogaster.34 To determine whether the 5′ phosphate was impor-
tant, we selected the as456 variant, which is an RNA-based 
oligonucleotide that contains a alternating 5′ OH, 2′ fluoro and 
hydroxyl groups (Figure 1b). Two variants of as456 were gen-
erated, either a 5′ T4 polynucleotide kinase phosphorylated 
or 5′ unphosphorylated variant. Both of these variants sup-
pressed LTR expression of luciferase equally well (Figure 2f) 
but the 5′ phosphorylated as456 appeared more susceptible 
to the suppression of Ago-1 than did the 5′ unphosphorylated 
variant (Figure 2f,g). Taken together these data suggest that 
as452, which lacks a 5′ phosphate, directs TGS in an HDAC-1 
dependent, but DNMT3a and Ago1 independent manner.
as452 is tolerant of mistmatches and does not cause an 
interferon response
In  order  to  determine  the  specificity  of  as452-mediated 
LTR-366  targeting,  we  generated  various  backbone-  and 
nucleotide-modified  variants  of  as452  (Figure  3a).  Initial 
screening  of  these  variants  ability  to  suppress  luciferase 
expression revealed that up to two mismatches (as725–as727, 
Figure 3a) were tolerated within the original as452 sequence 
as demonstrated by an appreciable efficacy in suppression. 
The addition of a third mismatch in as452 ablated its ability to 
suppress the LTR-366 target (as728 and as729) (Figure 3b). 
Interestingly, a simple change in the as452 sequence (variant 
as751) from a 2′-4′ LNA thymine to a 2′-O-methyl uracil dem-
onstrated an increased efficacy of suppression (Figure 3b). 
Moreover, the suppression instilled in the LTR by the action of 
as452 appeared Tat dependent at 50–100 nmol/l (Figure 3c), 
and  only  as452  remained  relatively  inert  when  contrasted 
with scrambled and as751   (Figure 3d). These data indicate 
(i) that scrambled controls are not as suitable for determin-
ing functionality as mock-treated cells as they appear to instill 
enhanced biological noise, and (ii) that backbone- and nucle-
otide-modified variants of as452 targeting the HIV-1 LTR-366 
can accommodate two mutations while retaining a relevant 
level of efficacy compared to as452. This observation may be 
therapeutically significant as it suggests TGS-active modified 
oligonuleotides may be able to retain suppression despite up 
to two mutations which in the case of HIV-1 may arise at the 
target site.35
Previous  studies  have  shown  that  ncRNA-directed TGS 
causes  site-specific  epigenetic  changes  to  the  ncRNA-
targeted  loci,  such  as  histone  3  lysine  27  tri-methylation 
(H3K27me3) and histone 3 lysine 9 di-methylation (H3K9me2) 
(reviewed in ref. 2,6). These silent state epigenetic changes 
appear to be required for long-term stable TGS to occur.10 Fur-
thermore, HDAC-1 appeared to be involved in the observed 
as452-mediated TGS of HIV-1 suggesting the possibility that 
as452 can target silent state epigenetic changes specifically 
at the LTR-366 target site. To determine the ability of as452 to 
target silent state epigenetic changes cultures were treated 
with either as452 or as751 and assayed for H3K9me2 and 
H3K27me3  enrichment  at  the  HIV-1  LTR-366  target  loci 
 ( Figure 1a) by chromatin immunoprecipitation (ChIP). The 
only notable enrichment observed was for H3K9me2 in the 
as452-treated  cultures  (Figure  3c). This  observation  sug-
gests  that  backbone-modified  as452-directed  TGS  is  due 
to epigenetic changes at the LTR-366 target site but also 
that this effect is sequence-specific as as751 did not cause 
methylation in the same region   (Figure 4a). When compared 
to  previous  studies,  the  relative  enrichment  of  H3K9me2 
observed at the as452 target site in the LTR-366 was notably 
lower.9–11,23,31 Therefore, in order to confirm that the epigenetic 
changes caused by as452 were correlative with a reduction 
in the amount of transcribed gene, nuclear run-on was per-
formed. The as452 exhibited a significant reduction in the 
amount of transcribed RNA when compared to as751 and 
mock-treated cells (Figure 4b). Supporting the notion that 
as452  is  suppressing  LTR-366  activity  in  a  transcriptional 
manner and that as751 may be functional in transcriptionally 
independent manner.
The experiments presented here are introducing synthetic 
chemically modified oligonucleotides to cells, therefore there 
is a risk of inducing a type-I interferon response. Type-I inter-
feron responses involve increased RIG1 and IFIH1 expres-
sion in response to foreign nucleic acids.36 To determine the www.moleculartherapy.org
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activation of interferon-related pathways by as452, we com-
pared the TLR3 activation in TZM-b1 by treatment with as452 
or the known activator Poly I:C. A modest increase in RIGI 
and IFIH1 was observed in the as452-treated cells; however, 
it was not greater than the variation observed between as452 
treated, mock treated, and untreated cells (Figure 4c). These 
data suggest that the previously observed suppression mod-
ulated by as452 does not appear to involve activation of the 
type-I interferon pathway.
as452  and  as751  block  LTR  expression  in  a TGS  and 
PTGS manner respectively
The above studies were performed in a TZM-bl reporter cell 
line and therefore, the ability of as452 to functionally suppress 
infectious HIV-1 remained unclear. To determine the efficacy 
of as452-mediated TGS in the context of an ongoing HIV-1 
infection; TZM-bl cells were infected with HIV-1 and subse-
quently treated with as452, as751 or the respective controls 
(as729 and R854, Figures 1a and 3a). Both LTR-expressed 
Figure 3  Tolerance of mismatches in antisense oligonucleotide-mediated TGS of HIV-1. (a) Several variations of the TGS inducing 
as452 antisense oligonucleotide were developed, containing specific variations. (b) The as452 variant antisense oligonucleotides were 
assessed for their ability to suppress HIV-1 LTR expressed luciferase in TZM-bl cells. (c,d) Dilution curve analysis of as452, as751, and 
scrambled controls standardized to the as729 control in (c) pTatDSRed or (d) untreated TZM-b1 cells. The cultures were assessed for 
luciferase protein expression 72 hours post-treatment. For a and b, the averages from triplicate transfected cultures are shown with the 
standard error of the means and the P values from a paired t-test. HIV-1, human immunodeficiency virus type 1; LTR, long terminal repeat; 
TGS, transcriptional gene silencing.
Sample
a
b
d
c
as452 as452 no mismatches
as452 with mismatch at bp 17
as452 with mismatch at bp 17
as452 with mismatch at bp 12, and bp17
as452 with mismatch at bp 9, 12, and 17
as452 with mismatch at bp 5, 9, 12, and 17
as452 internal T->U
Scrambled with mU
βC*βC*βT*mG*mG*mA*mA*mA*mG*βT*mC*βC*mC*βC*mA*mG*βC*βG*βG*
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luciferase and HIV-1 messenger RNA (mRNA) expression 
were suppressed in HIV-1–infected TZM-bl cells in a manner 
concordant with those values observed in TZM-bl cells con-
taining the integrated HIV-1 LTR-driven luciferase reporter 
activated by viral Tat protein expression (Figure 4d).
There was however a discrepancy observed between the 
suppression of luciferase, an indication of LTR-366 specific 
targeting, and HIV-1 in these cells (Figure 4d). Both 5′ and 
3′ LTRs contain the same sequence, which is the target for 
LTR-366 (Figure 1a), and therefore full-length HIV-1 can be 
effectively targeted by as452 and as751 in the viral 3′LTR/
mRNA. One plausible explanation for the previously observed 
differences  between  as452-  and  as751-based  suppression 
might  be  that  the  backbone-modified  oligonucleotides  are 
more suppressive of viral transcripts than the integrated LTR. 
In theory, the backbone-modified oligonucleotide molecules 
Figure 4  Effects of antisense oligonucleotides on epigenetic modulation of HIV-1 expression. (a,b) TZM-bl cells were transfected 
with pTatDSred and 24 hours later transfected with HIV-1 LTR-targeted antisense oligonucleotides, as452, as751 or R854 (control) (100 
nmol/l). Cultures were assessed for (a) H3K9me2 and H3K27me3 enrichment at the LTR by ChIP or (b) by nuclear run-on for transcrip-
tion of luciferase relative to β-actin. (c) Type-I interferon analysis in antisense oligonucleotide-treated TZM-bl cells. Both RIG-1 and IFIH1 
expression was assessed by qRT-PCR from as452-treated TZM-bl cells relative to mock controls, Poly I:C treated, or untreated cells. The 
averages are shown with the respective standard deviations. (d) TZM-bl cells were infected with HIV-1 (HX10, MOI = 0.1) and then 24 hours 
later transfected with antisense oligonucleotides (100 nmol/l, RNAiMax). The cultures were assessed 72 hours later for either luciferase or 
HIV-1 expression by qRT-PCR. (e) Culture RNAs from d were assessed by reverse transcription in the absence of a primer to determine 
possible self-priming capabilities as an indication of 3′ LTR targeting. For a, b, d, and e the averages of triplicate treated cultures are shown 
with the standard error of the mean (a, d, and e) or standard deviations (b only) and the P value from a paired t-test. ChIP, chromatin immu-
noprecipitation; HIV-1, human immunodeficiency virus type 1; LTR, long terminal repeat; MOI, multiplicity of infection; mRNA, messenger 
RNA; qRT-PCR, quantitative reverse transcription-PCR.
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might function in a bipartite manner such that in the context 
of an ongoing HIV-1 infection they might feasibly be inducing 
both TGS and also some level of either mRNA binding/block-
ing  or  post-transcriptional  gene  silencing  (PTGS).  In  order 
to determine whether or not this is the case total RNA from 
HIV-1 infected cells treated with as452, as751, as729 or mock 
treated were reverse transcribed in the absence of any primers 
and subsequently analyzed by quantitative PCR (qPCR) with 
primers specific for the LTR-366 loci. The notion being that if 
the backbone-modified oligonucleotides are binding the viral 
mRNA, a signal above the mock-treated cells would be evi-
dent. All of the oligonucleotide-treated cultures demonstrated 
appreciable increases above the mock-treated HIV-1 infected 
control  suggesting  that  there  is  some  binding  of  the  vari-
ous backbone-modified oligonucleotides to the HIV-1 mRNA 
 ( Figure 4e). Taken together these data suggest that the variant 
as452 is functional in suppressing HIV-1 in a bipartite manner 
whereas as751 and as729, which contains four mismatches, 
suppresses primarily through viral mRNA binding.
Discussion
Previous studies with duplexed RNAs containing backbone 
modifications demonstrated that various modifications in the 
passenger strand of the duplex RNAs such as 2′ fluoro-RNA, 
2′ OMe-RNA, and LNA substitutions or combinations of mul-
tiple modifications were permissive for siRNA-directed PTGS 
and recently, TGS and transcriptional gene activation of pro-
gesterone.37  Although  this  study  proved  highly  informative 
with regards to double-stranded RNA-based approaches to 
modulating TGS and/or transcriptional gene activation, it has 
remained unknown as to the efficacy of single-stranded back-
bone-modified antisense oligonucleotides at directing TGS. 
The emerging notion that natural antisense transcripts are 
endogenous effectors driving TGS and epigenetic regulation 
of genes in human cells suggest small asRNA mimics might 
prove useful with regards directing TGS in a therapeutic rel-
evant manner (reviewed in ref. 24,25,38). Data provided here 
indicates that the ability of single-stranded moieties to cause 
TGS is highly dependent upon sequence length, backbone 
chemistry, and that different protein pathways may be involved 
in the process depending on the particular molecule.
Several different molecules were found to be capable of 
directing suppression of the HIV-1 LTR include intermittent 
2′ fluoro, 2′ OMe, and LNA substitutions with the location of 
the particular modification proving important with regards to 
TGS function. While the observed suppression was as potent 
as previous observations of small asRNA or siRNA-directed 
TGS,9–11,29,31 there appeared to be a far less robust recruit-
ment of epigenetic silencing associated changes involved in 
the process observed here7,11 and these oligonucleotides did 
not fair as well as LNAs containing 2′-methoxyethyl bases.39 
Though these previous studies did not appreciate or assess 
the LNAs for transcriptional suppression as determined by 
nuclear run-on or epigenetic changes at the target loci39 as 
was done here. The lack of robust epigenetic changes could 
be due to an inability of as452 to efficiently utilize DNMT3a 
in the targeted silencing. Such an eventuality suggests that a 
different mechanism of TGS is being used to instill changes 
at the target loci, similar to observations by others who have 
targeted siRNAs directly at RNA polymerase II binding sites 
and TATA  which function in an  epigenetically independent 
manner.18,40  Furthermore,  observations  in  as452-treated 
HIV-1 infected TZM-bl cells indicated that TGS was operative 
at the LTR, as was evident by the suppression of luciferase 
expression in these cells, but that as452 is also suppressive 
by targeting the 3′ LTR in the context of the viral transcript in 
a manner similar to as751. While TZM-bl cells also contain 
the 3′ LTR when activated by Tat the level of expression is far 
lower than when an ongoing viral infection is present, sug-
gesting that the stoichiometry of target to oligonucleotide has 
an effect on how well TGS is established. These observations 
also suggest that combinations of as452 and as751 might 
provide increased efficacy in silencing as they appear to uti-
lize different modes of silencing.
Previous work has shown that synthetic siRNA duplexes 
with 5′-hydroxyl ends are rapidly phosphorylated inside cells 
by the cellular kinase Clp141 but it is unknown whether this 
occurs for single-stranded oligonucleotides. As shown here, 
the addition of a 5′ phosphate group to a chemically modified 
as456 altered the TGS pathway from Ago-1 independence 
to  increased  Ago-1  dependence.  This  is  in  keeping  with 
recent results that show an essential requirement for a 5′ 
phosphate group in order for proper loading and processing 
of microRNA and acts as a checkpoint for the microRNA in 
procession through the RNA-induced silencing complex and 
subsequent silencing of its target mRNA.34
Although  the  observations  presented  here  indicate  that 
single-stranded  antisense  oligonucleotides  with  particular 
backbone modifications can be utilized in targeted TGS in 
human cells there appear to be distinct shortcomings with 
these moieties. Most notably these molecules do not appear 
to epigenetically target the LTR-366 loci as profoundly as has 
been observed previously with other small RNAs targeted to 
the same LTR-366 loci but expressed either via vector trans-
fection (asRNAs, shRNAs) or synthetically derived transiently 
transfected  siRNAs.7,9,11,29  The  lack  of  robust  epigenetic 
silencing suggests that this form of suppression, although 
transcriptional in nature, will not be long-lasting and herita-
ble.10 Although the reason for the difference in epigenetic 
modifications is not entirely clear it is highly plausible that the 
inherent chemical charges on the backbone of the chemically 
modified  antisense  oligonucleotides  affect  binding  interac-
tions with the target loci, which in this case is a promoter-
associated transcript,11,17,19 or with those proteins, such as 
DNMT3a, which is required for ncRNA-directed epigenetic 
silencing.7,15 Taken together the data provided here suggests 
that  an  alternative  non-epigenetic–driven  mechanism  can 
be utilized by particular chemically modified antisense oli-
gonucleotides to transcriptionally modulate gene expression 
in human cells. Such a mechanism may prove useful as a 
means to control gene transcription while minimizing impacts 
on the endogenous ncRNA pathway in human cells.24,42
Materials And Methods
Cell cultures. TZM-bl cultures were grown at 37 °C in 5% CO2 
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cells with the Tat expressing plasmid pTatDSred43 (1.6 μg/106 
cells) was carried out using Lipofectamine 2000 according to 
the manufacturer’s specifications (Life Technologies, Carls-
bad,  CA).  The  respective  antisense  oligonucleotides  were 
provided (Coley/Pfizer, Dusseldorf, Germany) and transfected 
into TZM-bl cells 24 hours after Tat transfection in a dropwise 
manner  to  a  final  concentration  of  100  nmol/l  using  Lipo-
fectamine RNAiMAX (Life Technologies). The sequences of 
these various oligonucleotides used in this study are provided 
in Figures 1 and 2. The cultures were assessed for luciferase 
expression (primers in Supplementary Table S1), as an indi-
cation of LTR transcriptional fidelity at 48 or 72 hours after 
antisense oligonucleotide treatment and data standardized to 
the control, RNA 854, giving a value of 1.
ChIP  analysis.  ChIPs  were  performed  as  follows;  TZM-bl 
cells (106/10 cm plate) were transfected with 1.6 μg pTatD-
Sred. Twenty-four hours later TZM-bl cells were transfected 
with either as452 or as751 (final concentration 100 nmol/l, 
Lipofectamine 2000 (Life Technologies)). Seventy-two hours 
after oligonucleotide transfection the cells were cross-linked 
and ChIP performed as described in 11,17 with the following 
modification: chromatin was sonicated with a Misonix S-4000 
using 2 × 90 seconds pulses at amplitude 4 with 120 sec-
onds  rest  in  between. The  immuno-precipitated  DNA  was 
recovered by phenol/chloroform extraction and ethanol pre-
cipitation. DNA was then analyzed by qPCR using indicated 
primers (Supplementary Table S1) (Kapa Sybr Fast; Kapa 
Biosystems).
Nuclear run-on. Nuclear run-on was performed as described 
previously  (Hawkins  and  Morris  2010).  The  protocol  was 
modified to include the use of bioitin-16-UTP (Trilink, San 
Diego, CA). Biotinylated RNA was pulled down using Dynal 
C1  beads  (Dynal;  Life Technologies).  cDNA  copies  of  the 
RNA  were  generated  using  M-MLV  reverse  transcriptase 
(Life Technologies) and then analyzed by qPCR using the 
indicated primers (Kapa Sybr Fast; Kapa Biosystems). Data 
was standardized to β-actin expression and then normalized 
to mock control values.
qRT-PCR analysis of gene expression. RNA was extracted 
(RNeasy;  Qiagen, Valencia,  CA)  using  the  QiaCube  (Qia-
gen) and DNase treated (TURBO DNase; Life Technologies), 
reverse  transcribed  using  nonspecific  primers  (Reverse 
Transcription  Core  Kit;  Eurogentec,  San  Diego,  CA,  and 
analyzed by qPCR using indicated primers (Kapa Sybr Fast; 
Kapa  Biosystems)  (Supplementary  Table  S1).  Results 
from qPCR were normalized first to internal glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) (primers reported in 
ref. 7,10,11,17) or β-actin levels (Supplementary Table S1) 
and then expressed as fractions of control values.
Suppression  of  HDAC-1  and  DNMT3a. TZM-bl  cells  were 
plated in a 12-well plate (5 × 104/well) and transfected with 
pTatDSred  (80  ng).  For  DNMT3a  suppression,  Mission 
shRNA plasmids targeted to DNMT3a or an irrelevant control 
(300 ng) (Mission shRNAs; Sigma-Aldrich, St Louis, MO, a 
gift from Carol Kreider) were cotransfected with pTatDSred. 
HDAC-1  expression  was  suppressed  by  cotransfection  of 
an HDAC-targeted siRNA (Hawkins and others 2009) or the 
appropriate irrelevant control siRNA (R854)(final concentra-
tion 100 nmol/l) 24 hours later the cultures were transfected 
with the HIV-1 targeted as452 or control (final concentration 
of 100 nmol/l). Forty-eight hours post-transfection the cells 
were collected and luciferase, DNMT3a, or HDAC-1 expres-
sion  determined  by  quantitative  reverse  transcription-PCR 
(qRT-PCR) using DNMT3a, HDAC-1 forward/reverse primers 
(Supplementary Table S1).
MeDIP. TZM-bl cells were TZM-bl cells were cotransfected 
with pTatDSred and 24 hours later the cultures were trans-
fected with either as452 or the RNA control R854 (final con-
centration 100 nmol/l). The MeDIP assay was performed as 
described in 44 was performed with the following changes. 
AluI was replaced was MseI, 1 μg of digested DNA was used 
and samples were incubated overnight with a monoclonal 
antibody against 5-methylcytidine (Active Motif, Carlsbad, 
CA). Data was normalized against input DNA with primers 
targeting the 366 region (362 primers, see Supplementary 
Table S1) and GAPDH promoter and then normalized to 
R854 to compare relative methylation levels of the target 
region.
Ago-1 knockdown. TZM-bl cells were plated (5 × 104 cells/
well) and transfected (Lipofectamine 2000; Life Technologies) 
with pTatDSred (80 ng) and a Mission shAgo-1 or Control 
plasmid (100 ng), respectively (Mission shRNAs; Sigma-Al-
drich, a gift from Carol Kreider). Twenty-four hours later the 
cultures were transfected with either as452 or the RNA con-
trol R854 (final concentration 100 nmol/l). The cultures were 
assessed for Ago-1 and luciferase expression at 48 hours 
after antisense oligonucleotide treatment.
5′ phosphate labelling of as456. An RNA-based oligonucle-
otide  targeted  against  the  366  region  (as366)  containing 
alternating 2′ fluoro and 2′ hydroxyl groups in addition to a 
5′  OH  was  purchased  from  Integrated  DNA Technologies 
(Coralville, IA). The oligonucleotide was 5′ end-labeled using 
T4 PNK (New England Biolabs, Ipswich, MA) for 30 minutes 
at 37 °C, purified via phenol/chloroform extraction, ethanol 
precipitated and resuspended in 10 mmol/l Tris-Cl, pH 8.5. 
The 5′ phosphate labeled as366 and non-labeled as366 con-
centration was determined using spectrofluorimetry. These 
oligonucelotides were then used as described in the method 
for Ago-1 knockdown.
as452 mutation analysis. TZM-bl cells (5 × 104/well in 12-well 
plate) were transfected with 80 ng pTatDSred. The following 
day the cultures were transfected using RNAiMAX with the 
following antisense oligonucleotides, as452, as725, as726, 
as727, as728, as729, and as751 (100 nmol/l), targeted to 
the  HIV-1  366  site.9,29  Forty-eight  hours  post-transfection, 
luciferase expression was measured by qRT-PCR and nor-
malized  to  β-actin  expression.  The  averages  of  triplicate 
treated  cultures  are  shown  with  the  standard  error  of  the 
means and P values from a paired t-test.
Detection  of  antisense  oligonucleotide  binding  HIV-1  tran-
scripts.  TZM-bl  cells  were  infected  with  HIV-1  (HX10, www.moleculartherapy.org
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multiplicity of infection = 0.1) and 24 hours later transfected 
with various antisense oligonucleotides (100 nmol/l, RNAiMax; 
Life Technologies). The cultures were collected and assessed 
72 hours later for luciferase or HIV-1 expression by qRT-PCR. 
To determine whether the antisense oligonucleotides were 
binding the 3′ LTR of HIV-1, a total of 400 ng of culture RNA 
was isolated, DNase treated and reverse transcribed in the 
absence of any primer. The resultant cDNAs were used in 
qPCR for HIV-1 with primers p128 and p129 (Supplemen-
tary Table S1).
Dilution analysis of oligonucleotides. TZM-bl cells (1.2 × 104/
well in 96-well plate) were transfected with 20 ng pTatDSred. 
Six hours later the media was replaced and cells were trans-
fected  with  oligonucleotides  as452,  as729,  as750,  as751, 
each at concentrations of 5 nmol/l, 10 nmol/l, 50 nmol/l, and 
100 nmol/l (RNAiMAX; Life Technologies). Seventy-two hours 
later, 100 μl of ONE-Glo Luciferase Assay reagent was added 
to each well (Promega, Madison, WI). The plate was incu-
bated at room temperature for 10 minutes, and luminescence 
intensity was measured using a Clarity Microplate Luminom-
eter (BioTek, Winooski, VT). Luminosity measurements were 
taken at 1 second/well.
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